BTIG analyst David Larsen downgrades Signify Health (NYSE:SGFY) from Buy to Neutral.
Krystal Biotech Receives FDA Approval For First-Ever Redosable Gene Therapy, VYJUVEK For Treatment Of Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of production of